|
1
|
Naora H and Montell DJ: Ovarian cancer
metastasis: integrating insights from disparate model organisms.
Nat Rev Cancer. 5:355–366. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
2
|
Schmitt J and Matei D: Targeting
angiogenesis in ovarian cancer. Cancer Treat Rev. 38:272–283. 2012.
View Article : Google Scholar
|
|
3
|
Davidson B, Tropé CG and Reich R:
Epithelial-mesenchymal transition in ovarian carcinoma. Front
Oncol. 2:332012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Comamala M, Pinard M, Theriault C, et al:
Downregulation of cell surface CA125/MUC16 induces
epithelial-to-mesenchymal transition and restores EGFR signalling
in NIH:OVCAR3 ovarian carcinoma cells. Br J Cancer. 104:989–999.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Cheng JC, Auersperg N and Leung PC:
EGF-induced EMT and invasiveness in serous borderline ovarian tumor
cells: a possible step in the transition to low-grade serous
carcinoma cells? PLoS One. 7:e340712012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Cheng JC, Auersperg N and Leung PC:
TGF-beta induces serous borderline ovarian tumor cell invasion by
activating EMT but triggers apoptosis in low-grade serous ovarian
carcinoma cells. PLoS One. 7:e424362012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bagnato A and Rosanò L:
Epithelial-mesenchymal transition in ovarian cancer progression: a
crucial role for the endothelin axis. Cells Tissues Organs.
185:85–94. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ahmed N, Thompson EW and Quinn MA:
Epithelial-mesenchymal interconversions in normal ovarian surface
epithelium and ovarian carcinomas: an exception to the norm. J Cell
Physiol. 213:581–588. 2007. View Article : Google Scholar
|
|
9
|
Elloul S, Vaksman O, Stavnes HT, Tropé CG,
Davidson B and Reich R: Mesenchymal-to-epithelial transition
determinants as characteristics of ovarian carcinoma effusions.
Clin Exp Metastasis. 27:161–172. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yilmaz M and Christofori G: EMT, the
cytoskeleton, and cancer cell invasion. Cancer Metastasis Rev.
28:15–33. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Onder TT, Gupta PB, Mani SA, Yang J,
Lander ES and Weinberg RA: Loss of E-cadherin promotes metastasis
via multiple downstream transcriptional pathways. Cancer Res.
68:3645–3654. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wang Y, Wen M, Kwon Y, et al: CUL4A
induces epithelial-mesenchymal transition and promotes cancer
metastasis by regulating ZEB1 expression. Cancer Res. 74:520–532.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Huang RY, Chung VY and Thiery JP:
Targeting pathways contributing to epithelial-mesenchymal
transition (EMT) in epithelial ovarian cancer. Curr Drug Targets.
13:1649–1653. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wang Y, Liu Y, Lu J, et al: Rapamycin
inhibits FBXW7 loss-induced epithelial-mesenchymal transition and
cancer stem cell-like characteristics in colorectal cancer cells.
Biochem Biophys Res Commun. 434:352–356. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lu J, Wen M, Huang Y, et al: C2ORF40
suppresses breast cancer cell proliferation and invasion through
modulating expression of M phase cell cycle genes. Epigenetics.
8:571–583. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wang Y, Ma G, Wang Q, et al: Involvement
of CUL4A in regulation of multidrug resistance to P-gp substrate
drugs in breast cancer cells. Molecules. 19:159–176. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Rosano L, Spinella F, Di Castro V, et al:
Endothelin-1 promotes epithelial-to-mesenchymal transition in human
ovarian cancer cells. Cancer Res. 65:11649–11657. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Peinado H, Olmeda D and Cano A: Snail, Zeb
and bHLH factors in tumour progression: an alliance against the
epithelial phenotype? Nat Rev Cancer. 7:415–428. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hollier BG, Tinnirello AA, Werden SJ, et
al: FOXC2 expression links epithelial-mesenchymal transition and
stem cell properties in breast cancer. Cancer Res. 73:1981–1992.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Nishida N, Mimori K, Yokobori T, et al:
FOXC2 is a novel prognostic factor in human esophageal squamous
cell carcinoma. Ann Surg Oncol. 18:535–542. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kajiyama H, Kikkawa F, Suzuki T, Shibata
K, Ino K and Mizutani S: Prolonged survival and decreased invasive
activity attributable to dipeptidyl peptidase IV overexpression in
ovarian carcinoma. Cancer Res. 62:2753–2757. 2002.PubMed/NCBI
|
|
22
|
Mortazavi F, An J, Dubinett S and Rettig
M: p120-catenin is transcriptionally downregulated by FOXC2 in
non-small cell lung cancer cells. Mol Cancer Res. 8:762–774. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Fu J, Lv X, Lin H, et al: Ubiquitin ligase
cullin 7 induces epithelial-mesenchymal transition in human
choriocarcinoma cells. J Biol Chem. 285:10870–10879. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yuan H, Kajiyama H, Ito S, et al: ALX1
induces snail expression to promote epithelial-to-mesenchymal
transition and invasion of ovarian cancer cells. Cancer Res.
73:1581–1590. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Tiwari N, Gheldof A, Tatari M and
Christofori G: EMT as the ultimate survival mechanism of cancer
cells. Semin Cancer Biol. 22:194–207. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Schmalhofer O, Brabletz S and Brabletz T:
E-cadherin, betacatenin, and ZEB1 in malignant progression of
cancer. Cancer Metastasis Rev. 28:151–166. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Katsuno Y, Lamouille S and Derynck R:
TGF-beta signaling and epithelial-mesenchymal transition in cancer
progression. Curr Opin Oncol. 25:76–84. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wendt MK, Allington TM and Schiemann WP:
Mechanisms of the epithelial-mesenchymal transition by TGF-beta.
Future Oncol. 5:1145–1168. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Nougaret S, Addley HC, Colombo PE, et al:
Ovarian carcinomatosis: how the radiologist can help plan the
surgical approach. Radiographics. 32:1775–1803. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Tsai JH and Yang J: Epithelial-mesenchymal
plasticity in carcinoma metastasis. Genes Dev. 27:2192–2206. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zhu JL, Song YX, Wang ZN, et al: The
clinical significance of mesenchyme forkhead 1 (FoxC2) in gastric
carcinoma. Histopathology. 62:1038–1048. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Watanabe T, Kobunai T, Yamamoto Y, et al:
Gene expression of mesenchyme forkhead 1 (FOXC2) significantly
correlates with the degree of lymph node metastasis in colorectal
cancer. Int Surg. 96:207–216. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
33
|
Mani SA, Yang J, Brooks M, et al:
Mesenchyme Forkhead 1 (FOXC2) plays a key role in metastasis and is
associated with aggressive basal-like breast cancers. Proc Natl
Acad Sci USA. 104:10069–10074. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Seo S, Fujita H, Nakano A, Kang M, Duarte
A and Kume T: The forkhead transcription factors, Foxc1 and Foxc2,
are required for arterial specification and lymphatic sprouting
during vascular development. Dev Biol. 294:458–470. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Cederberg A, Grände M, Rhedin M, Peng XR
and Enerbäck S: In vitro differentiated adipocytes from a Foxc2
reporter knock-in mouse as screening tool. Transgenic Res.
18:889–897. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: the next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wicki A, Lehembre F, Wick N, Hantusch B,
Kerjaschki D and Christofori G: Tumor invasion in the absence of
epithelial-mesenchymal transition: podoplanin-mediated remodeling
of the actin cytoskeleton. Cancer Cell. 9:261–272. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Chou JL, Chen LY, Lai HC and Chan MW:
TGF-β: friend or foe? The role of TGF-β/SMAD signaling in
epigenetic silencing of ovarian cancer and its implication in
epigenetic therapy. Expert Opin Ther Targets. 14:1213–1223.
2010.
|
